Cover Image
市場調查報告書

癌症治療用血管新生抑制劑:全球市場及臨床實驗平台分析

Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight

出版商 KuicK Research 商品編碼 367807
出版日期 內容資訊 英文 660 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症治療用血管新生抑制劑:全球市場及臨床實驗平台分析 Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight
出版日期: 2016年08月25日 內容資訊: 英文 660 Pages
簡介

本報告提供癌症治療用血管新生抑制劑的市場與臨床實驗平台趨勢調查,血管新生及血管新生抑制劑概要,血管新生抑制劑的各種區分與用途,目前市場的狀況,市場的影響因素分析,臨床實驗平台趨勢,已上市藥物趨勢,以及主要企業的簡介等彙整。

第1章 血管新生:過程、治療方法的摸索

第2章 血管新生抑制劑:治癒、預防

  • 癌症的特徵
  • 抗癌藥治療的標的之血管新生的轉移性途徑

第3章 血管新生是什麼?

  • 血管新生的階段
  • 血管新生的類型

第4章 血管新生調節劑

  • VEGF與血管新生
  • PDGF (血小板來源成長因素)
  • FGF (纖維母細胞生長因子)&FGF受體
  • 內皮素&內皮素受體
  • 促血紅細胞生長素&促血紅細胞生長素受體
  • 血管生成素&Tie2受體

第5章 血管新生的機制

第6章 血管新生抑制劑的分類

  • 血管新生的直接內在性抑制劑
  • 血管新生的間接內在性抑制劑
  • 傳統的化療劑
  • VEGF標靶治療藥
  • FGF標靶治療藥
  • 致癌基因標靶治療藥
  • 矩陣分解&重塑標靶治療藥
  • 間品質癌細胞標靶治療藥
  • 細胞黏合分子 (CAM)標靶治療藥
  • 發炎性血管新生標靶治療藥

第7章 節拍器療法:抗血管新生治療新的發展

第8章 血管新生抑制劑的用途

  • 惡性疾病的定量化、預後
  • 抗血管新生療法
    • 癌症
    • 肝血管瘤治療用α干擾素2α
    • 眼血管新生

第9章 全球血管新生抑制劑市場:概要

  • 目前市場方案
  • 全球癌症的血管新生抑制劑:臨床實驗平台概要

第10章 全球癌症治療用血管新生抑制劑:市場動態

  • 有利的市場參數
  • 主要課題

第11章 總論、未來展望

第12章 全球癌症治療用血管新生抑制劑的臨床實驗平台:各企業、適應症、階段

  • 不明
  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段
  • 申請完畢

第13章 已上市癌症治療用血管新生抑制劑的臨床性考察:各企業、適應症

  • Apatinib
  • Lenalidomide (Ladevina & Revlimid)
  • Pomalidomide (Imnovid & Pomalyst)
  • Sorafenib (Nexavar)
  • Thalidomide (Thaled、Thalidomide Celgene、Thalomid)
  • Pazopanib (Votrient)
  • Bevacizumab (Avastin)
  • Bevacizumab Biosimilar (Cizumab)
  • Cetuximab (Erbitux)
  • Axitinib (Inlyta)
  • Recombinant Human Endostatin (Endostar & Endu)

第14章 中止、延期的臨床實驗平台:各企業、階段

  • 無發展報告
  • 中止
  • 延期

第15章 競爭環境

  • Advenchen Laboratories
  • Allergan
  • Alnylam Pharmaceuticals
  • Amgen
  • Angstrom Pharmaceuticals
  • Acceleron Pharma
  • Biocon
  • Bionomics
  • CASI Pharmaceuticals
  • Celgene Corporation
  • Enzon Pharmaceuticals
  • Five Prime Therapeutics
  • Fuji Film Kyowa Kirin Biologics
  • Genentech
  • Genexine
  • Hetero Drugs
  • ImClone Systems
  • Intas Pharmaceuticals
  • Kyowa Hakko Kirin
  • Levolta Pharmaceuticals
  • Mabtech
  • Marsala Biotech
  • Neumedicines
  • Novartis
  • Oncobiologics
  • Onyx Pharmaceuticals
  • Pfizer
  • Philogen
  • TBG Diagnostics
  • Reliance Life Sciences
  • Roche
  • Samsung Bioepis
  • Simcere Pharmaceutical Group
  • SynCore Biotechnology
  • TaiRx
  • Taiwan Liposome Company
  • Tiltan Pharma
  • XBiotech

圖表

目錄

Cancer is ever fastest growing global epidemic and one of the leading causes of death in the developed countries. It was observed that year 2015 alone witnessed more than 10 million new cancer cases. The number of new cancer cases is predicted to rise to 22 million within the next two decades. More than 60 percent of the world's new cancer cases occur in Africa, Asia, and Central and South America; 70 percent of the world's cancer deaths also occur in these regions. The future burden will probably be even larger because of the adoption of western lifestyles, such as smoking, poor diet, physical inactivity, and fewer childbirths, in economically developing countries.

Owing to this, the cancer segment of pharmaceutical industry is most studied and highly competitive in nature. The chemotherapeutic products are extremely diverse ranging from monoclonal antibodies, vaccines, immunomodulators, and hormonal therapies to bispecific monoclonal antibodies including the miscellaneous drugs. All the aforementioned drugs are formulated in a way to be step ahead in targeted approach from their predecessor. Nevertheless, all the above mentioned therapies have their own limitations; either they should be given in conjunction with other therapies, require high dose or have got enormous side effects and so on. They too have different pharmacological parameters, overlapping boundaries and cost effectiveness.

One of the major segments of cancer therapy is occupied by the angiogenesis inhibitors. The market for angiogenesis inhibitors is quiet optimistic as they have emerged as the new targeted therapy for the cancer treatment. These molecules due their specificity are gaining a lot of manufacturer's interest. With advent of new and improved technology, angiogenesis inhibitors therapy witnessed a drastic transition and is becoming more acceptable due to its site specific approach. They have become a critical component of clinical treatment procedure for a variety of indications.

Angiogenesis is an important hallmark of tumor development. Hence, targeting angiogenesis is for sure help to eradicate the cancer. Similarly, metastasis is now a validated target for cancer treatment, the overall benefits of anti-angiogenic drugs from the perspective of impacting survival have left much to desire, endorsing a need for developing more effective therapeutic regimens. The anti angiogenic drugs are being combined with established conventional chemotherapeutic drugs to produce the desirable effect. There are now several agents available in the market such as bevacizumab that target the tumor vasculature through different pathways, either by inhibiting formation of the tumor neovasculature or by directly targeting the mature tumor vessels.

Although it has been found that their effects are compounded by their synergistic use with conventional chemotherapy rather than individual agents. For instance, an antiangiogenic drug such as bevacizumab is potent enough to bring about a transient functional normalization of the tumor vasculature. So, in order to get the maximum results out of it; this can be co-administered with chemo/radiotherapy.

Therapeutic innovations in various segments have made the transition from human conception to clinical reality over the past two decades and reached from labs to bedside of the patients. Now, many of angiogenesis inhibitors are being tested as adjuvant or first-line therapies to determine their efficacy in improving survival. Although majorly angiogenesis inhibitors are used as supportive therapy rather than streamline drugs as they take huge time to even show reasonable results. The market is no doubt flourishing and is sure to increase many folds as with due acceptance of clinicians and patients due to their targeted effect.

In future, the information drawn from genome medical science and genome-informatics that clearly identifies the disease centric antigens valuable for medical treatment is being employed to develop the therapy using mAbs. Currently, the more attention is getting paid toward targeted therapy. Several angiogenesis inhibitors, alone and in combination with other conventional therapies, are being tested in phase I and phase II clinical trials at the moment. The health market in coming years is sure to get loaded with BsAbs with prior approval of these prospective drugs.

Hence, it is quiet predictable that global market for angiogenesis inhibitors for cancer treatment is expected to register a healthy annual market growth rate during the forecast period. The healthy growth rate can be related to the cumulative effects such as fast technological development, upsurge in the number of incidences of cancer patients, rise in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe.

“Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight” Report Highlights:

  • Angiogenesis Inhibitors: Introduction & Need in Cancer Therapy
  • Modulators & Mechanism of Angiogenesis
  • Classification of Angiogenesis Inhibitors
  • Metronomic Therapy - A Recent Advancement in Anti-Angiogenesis Therapy
  • Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Company, Indication & Phase
  • Global Cancer Angiogenesis Inhibitors Clinical Pipeline: 146 Drugs
  • Marketed Cancer Angiogenesis Inhibitors Drugs: 11 Drugs

Table of Contents

1. Angiogenesis: History and Quest for Treatment

2. Angiogenesis Inhibitors: An Ounce of Cure & Prevention

  • 2.1. Hallmarks of Cancer
    • 2.1.1. Self Sufficiency in Growth Signals
    • 2.1.2. Insensitivity to Antigrowth Signals
    • 2.1.3. Acquired Capability: Evading Apoptosis
    • 2.1.4. Limitless Replicative Potential
    • 2.1.5. Sustained Angiogenesis
    • 2.1.6. Tissue Invasion & Metastasis
  • 2.2. Angiogenic- Metastatic Pathway as a Target for Anti-Cancer Therapies

3. What is Angiogenesis?

  • 3.1. Stages of Angiogenesis
  • 3.2. Types of Angiogenesis
    • 3.2.1. Sprouting Angiogenesis
    • 3.2.2. Intussusceptive Angiogenesis or Splitting Angiogenesis

4. Modulators of Angiogenesis

  • 4.1. VEGF & Angiogenesis
  • 4.2. Platelet Derived Growth Factor
  • 4.3. Fibroblast Growth Factors (FGFs) & FGF Receptors
  • 4.4. Endothelins & Endothelin Receptors
  • 4.5. Erythropoietin & Erythropoietin Receptor
  • 4.6. Angiopoietins & Tie2 Receptor

5. Mechanism of Angiogenesis

  • 5.1. Dilation of Existing Vessels, Increase in Vascular Permeability & Degradation of Existing Vessels
  • 5.2. Endothelial Cells Proliferation & Migration
  • 5.3. Assembling of Endothelial Cells, Formation of Cords & Lumen
  • 5.4. Long-Term Survival of Vascular Endothelium
  • 5.5. Differentiation of Vascular Endothelium to Meet Local Needs

6. Classification of Angiogenesis Inhibitors

  • 6.1. Direct Endogenous Inhibitors of Angiogenesis
  • 6.2. Indirect Inhibitors of Angiogenesis
  • 6.3. Conventional Chemotherapeutic Agents
  • 6.4. VEGF Targeted Therapy
  • 6.5. FGF Targeted Therapies
  • 6.6. Oncogene Targeted Therapy
  • 6.7. Matrix Degrading & Remodeling Targeted Therapy
  • 6.8. Stromal Tumor Associated Cell Targeted Therapy
  • 6.9. Cell Adhesion Molecules (CAMs) Targeted Therapy
  • 6.10. Inflammatory Angiogenesis Targeted Therapy

7. Metronomic Therapy - A Recent Advancement in Anti-Angiogenesis Therapy

8. Applications of Angiogenesis Inhibitors

  • 8.1. Quantitation & Prognosis of Malignant Disorders
  • 8.2. Antiangiogenic Therapies
    • 8.2.1. Cancer
    • 8.2.2. Interferon Alpha-2α to Treat Hemangiomas
    • 8.2.3. Ocular Neovascularization

9. Global Angiogenesis Inhibitors Market overview

  • 9.1. Current Market Scenario
  • 9.2. Global Cancer Angiogenesis Inhibitors Clinical Pipeline Overview

10. Global Cancer Angiogenesis Inhibitors Market Dynamics

  • 10.1. Favorable Market Parameters
    • 10.1.1. Large Global Patient Pool
    • 10.1.2. Severity of the Disease
    • 10.1.3. Side Effects of the Existing Drugs
    • 10.1.4. Unmet Requirement of Completely Curative Agents
  • 10.2. Major Challenges of Cancer Angiogenesis Inhibitors Market
    • 10.2.1. Difficulties Associated with Evaluation of Anti Angiogenic Effect of Drugs
    • 10.2.2. Prospects of Delayed Toxicity with Long-Term Anti-Angiogenic Therapy
    • 10.2.3. Need of the Better Therapy Models
    • 10.2.4. Approval from Regulatory Guidelines: A Major Challenge
    • 10.2.5. Journey of Drug from Bench to Bedside: A Matter of Money & Time

11. Concluding Remarks & Future Market Prospects

12. Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 12.1. Unknown
  • 12.2. Research
  • 12.3. Preclinical
  • 12.4. Clinical
  • 12.5. Phase-I
  • 12.6. Phase-I/II
  • 12.7. Phase-II
  • 12.8. Phase-II/III
  • 12.9. Phase-III
  • 12.10. Preregistration

13. Marketed Cancer Angiogenesis Inhibitors Clinical Insight by Company & Indication

  • 13.1. Apatinib
  • 13.2. Lenalidomide (Ladevina & Revlimid)
  • 13.3. Pomalidomide (Imnovid & Pomalyst)
  • 13.4. Sorafenib (Nexavar)
  • 13.5. Thalidomide (Thaled, Thalidomide Celgene & Thalomid)
  • 13.6. Pazopanib (Votrient)
  • 13.7. Bevacizumab (Avastin)
  • 13.8. Bevacizumab Biosimilar (Cizumab)
  • 13.9. Cetuximab (Erbitux)
  • 13.10. Axitinib (Inlyta)
  • 13.11. Recombinant Human Endostatin (Endostar & Endu)

14. Discontinued & Suspended Cancer Angiogenesis Inhibitors Clinical Pipeline by Company & Phase

  • 14.1. No Development Reported
  • 14.2. Discontinued
  • 14.3. Suspended

15. Competitve Landscape

  • 15.1. Advenchen Laboratories
  • 15.2. Allergan
  • 15.3. Alnylam Pharmaceuticals
  • 15.4. Amgen
  • 15.5. Angstrom Pharmaceuticals
  • 15.6. Acceleron Pharma
  • 15.7. Biocon
  • 15.8. Bionomics
  • 15.9. CASI Pharmaceuticals
  • 15.10. Celgene Corporation
  • 15.11. Enzon Pharmaceuticals
  • 15.12. Five Prime Therapeutics
  • 15.13. Fujifilm Kyowa Kirin Biologics
  • 15.14. Genentech
  • 15.15. Genexine
  • 15.16. Hetero Drugs
  • 15.17. ImClone Systems
  • 15.18. Intas Pharmaceuticals
  • 15.19. Kyowa Hakko Kirin
  • 15.20. Levolta Pharmaceuticals
  • 15.21. Mabtech
  • 15.22. Marsala Biotech
  • 15.23. Neumedicines
  • 15.24. Novartis
  • 15.25. Oncobiologics
  • 15.26. Onyx Pharmaceuticals
  • 15.27. Pfizer
  • 15.28. Philogen
  • 15.29. TBG Diagnostics
  • 15.30. Reliance Life Sciences
  • 15.31. Roche
  • 15.32. Samsung Bioepis
  • 15.33. Simcere Pharmaceutical Group
  • 15.34. SynCore Biotechnology
  • 15.35. TaiRx
  • 15.36. Taiwan Liposome Company
  • 15.37. Tiltan Pharma
  • 15.38. XBiotech

List of Tables

  • Table 1-1: List of the Major Events in History of Angiogenesis Inhibitors Development
  • Table 2-1: List of FDA Approved Drugs & Their Target Cancer
  • Table 4-1: List of Some Angiogenesis Inhibitors & Their Target Receptors

List of Figures

  • Figure 3-1: Different Stages of Involved in Angiogenesis
  • Figure 3-2: Different Types of Angiogenesis
  • Figure 3-3: Steps Involved in Sprouting Angiogenesis
  • Figure 3-4: Steps Involved in Splitting Angiogenesis
  • Figure 4-1: Different Types of Modulators of Angiogenesis
  • Figure 4-2: Pathway Followed by VEGF during Angiogenesis
  • Figure 4-3: Modulatory Pathway of FGF in Angiogenesis
  • Figure 4-4: Basic Pathway Followed by Modulators to Facilitate Angiogenesis
  • Figure 5-1: Mechanism of Angiogenesis Stimulated by Tumor Cells
  • Figure 6-1: Various Categories of Angiogenesis Inhibitors
  • Figure 8-1: Important Applications of Angiogenic Inhibitors
  • Figure 9-1: Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Phase (%), 2016
  • Figure 9-2: Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Phase (Numbers), 2016
  • Figure 9-3: Global Cancer Angiogenesis Inhibitors Suspended & Discontinued in Clinical Pipeline (%), 2016
  • Figure 9-4: Global Cancer Angiogenesis Inhibitors Suspended & Discontinued in Clinical Pipeline (Numbers), 2016
  • Figure 10-1: Favorable Parameters for Cancer Angiogenesis Inhibitors Market
  • Figure 10-2: Major Challenges of Cancer Angiogenesis Inhibitors Market
  • Figure 15-1: Advenchen Laboratories - Clinical Pipeline
  • Figure 15-2: Alexion Pharmaceuticals - Clinical Pipeline
  • Figure 15-3: Alnylam Pharmaceuticals - Clinical Pipeline
  • Figure 15-4: Amgen - Clinical Pipeline
  • Figure 15-5: Acceleron Pharma - Clinical Pipeline
  • Figure 15-6: Biocon - Clinical Pipeline
  • Figure 15-7: Bionomics - Clinical Pipeline
  • Figure 15-8: Casi Pharmaceutical - Clinical Development
  • Figure 15-9: Celgene - Clinical Pipeline
  • Figure 15-10: Five Prime Therapeutics - Clinical Pipeline
  • Figure 15-11: Fujifilm Kyowa Kirin Biologics - Clinical Pipeline
  • Figure 15-12: Genexine - Clinical Pipeline
  • Figure 15-13: Levolta Pharmaceuticals - Clinical Pipeline
  • Figure 15-14: Neumedicines - Clinical Pipeline
  • Figure 15-15: Novartis - Clinical Pipeline
  • Figure 15-16: Oncobiologics - Clinical Pipeline
  • Figure 15-17: Philogen - Clinical Pipeline
  • Figure 15-18: Samsung Bioepis - Clinical Pipeline
  • Figure 15-19: Simcere Pharmaceutical Group - Clinical Pipeline
  • Figure 15-20: SynCore Biotechnology - Clinical Pipeline
Back to Top